Please Wait...

Serum Amyloid A (SAA)

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

SAA is an acute phase protein, mainly produced by the liver and released in response to inflammation or infections. Indeed, SAA production is stimulated by pro-inflammatory cytokines such as IL-6, IL-1 and TNF-α (Calabrò et al., 2010). SAA has a role in cholesterol metabolism as it circulates in low levels bound to High-Density Lipoprotein (HDL) (Coetzee et al., 1986). During inflammation, SAA levels strongly increase and the protein can constitute up to 80% of HDL apolipoproteins. SAA is also a precursor of amyloid A protein, an insoluble product whose pathological accumulation is named amyloidosis (Husebekk et al., 1985). Blood levels of SAA are increased in numerous inflammatory disorders including Rheumatoid Arthritis (Targonska-Stepniak and Majdan, 2014) .

Bioclinica Lab employs a manual sandwich immunoassay for the measurement of human SAA in serum.

Calabrò, P., Riegler, L., Limongelli, G., Maddaloni, V., Martone, F., Golia, E., D’Alessandro, R., Pacileo, G., Russo, M.G., Golino, P., et al. (2010). Production of Serum Amyloid a in Response to Inflammatory Cytokines by Human Adipocytes. Eur. J. Inflamm. 8, 99–105.

Coetzee, G.A., Strachan, A.F., van der Westhuyzen, D.R., Hoppe, H.C., Jeenah, M.S., and de Beer, F.C. (1986). Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J. Biol. Chem. 261, 9644–9651.

Husebekk, A., Skogen, B., Husby, G., and Marhaug, G. (1985). Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand. J. Immunol. 21, 283–287.

Targonska-Stepniak, B., and Majdan, M. (2014). Serum Amyloid A as a Marker of Persistent Inflammation and an Indicator of Cardiovascular and Renal Involvement in Patients with Rheumatoid Arthritis. Mediators Inflamm. 2014, e793628.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Still time to catch up on summer reading on recent developments in #Alzheimer's Disease Fluid Biomarkers here int t… https://t.co/kyQmz7FxlN
bioclinica (Yesterday)
Our clients have substantial success w #eSource, some spanning well over a decade. Still other organizations remain… https://t.co/UwVs6ajPp4
bioclinica (2 days ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still some in the industry remai… https://t.co/ASuUvN6xb9
bioclinica (4 days ago)
RT @RfwrightLSL: When Do You Think #BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In #Clinical #Research? https:…
bioclinica (1 week ago)
ICYMI: Our V.P./Head of Neuroscience & Cardiovascular Svcs., Dr. Joyce Suhy, talks about challenges in determining… https://t.co/Lns6B3VPPN
bioclinica (1 week ago)
RT @FCR_News_Today: FDA Issues New Guides on Use of Electronic Health Information in #ClinicalTrials. #ClinicalResearch https://t.co/j8LHV2…
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen